Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking ...

Monopoly Go players who need extra tokens to progress through the latest Adventure Club event should give Viking Voyage a go. This new Monopoly Go event launched alongside the return of the ...

Stanley Black & Decker has reportedly settled a patent dispute it had with Norway-based Viking Arm involving Viking Arm’s construction jack patents and Stanley Black & Decker’s Stanley Fatmax ...

Article continues below It also boasts the Wild West-themed Frontier Falls, and the newest Viking zone where there are big rollercoasters for thrillseekers like Accelerator, as well as the popular ...

Indianapolis-based The Heritage Group has discontinued its business accelerator program after a six-year run. The Heritage Group is a privately held Indianapolis-based holding company with an ...

That’s one key focus of the team at Healthworx, a Blues plan-backed investment firm and accelerator that seeks to turbocharge the latest innovations. Senior Writer Paige Minemyer sat down with ...

Viking soared more than 100% in one trading session last year on positive clinical trial news. The stock has since given up those gains, but its weight loss drug program continues to advance and ...

Healio is the official media partner for the CancerX 2025 Accelerator cohort. The cohort is comprised of innovative startups focused on addressing critical challenges in oncology. Healio is ...

Obesity upstart Viking Therapeutics has agreed to pay a total of $150 million through 2028 to enlist CordenPharma for production of its dual GIP/GLP-1 agonist VK2735. Under the deal, CordenPharma ...

Viking will continue to grow its fleet, with the addition of 26 river ships and nine ocean ships by 2030. Photo Credit: Viking Viking Holdings told investors Tuesday during its Q4 earnings call ...

Viking stock soared a year ago on positive clinical trial data from its weight loss drug candidate. That candidate continues to progress, but Viking’s stock has tumbled from its peak. Last week ...